×

Cystic fibrosis transmembrane conductance regulator gene mutations

  • US 7,820,388 B2
  • Filed: 11/09/2007
  • Issued: 10/26/2010
  • Est. Priority Date: 12/22/2006
  • Status: Active Grant
First Claim
Patent Images

1. A method of determining the cystic fibrosis status of a human, comprising:

  • (a) determining the presence or absence of the 630delG mutation in both alleles of the cystic fibrosis transmembrane regulatory (CFTR) gene of the human in a nucleic acid sample obtained from the human, and(b) identifying the human(i) as having cystic fibrosis or being predisposed to cystic fibrosis when the human is homozygous for the 630delG mutation in the CFTR gene, or(ii) as being a cystic fibrosis carrier when the human is heterozygous for the 630delG mutation in the CFTR gene, or(iii) as having no predisposition or carrier status caused by the 630delG mutation when the 630delG mutation is absent from both alleles of the CFTR gene.

View all claims
  • 0 Assignments
Timeline View
Assignment View
    ×
    ×